Business
Lobe Sciences Congratulates Australia for Becoming the First Nation to Approve the Medicinal Use of Psilocybin and MDMA
Vancouver, British Columbia--(Newsfile Corp. - February 6, 2023) - Lobe Sciences Ltd. (CSE: LOBE)...
About this update from Lobe Sciences Ltd
[{"type":"text","content":"Lobe Sciences Congratulates Australia for Becoming the First Nation to Approve the Medicinal Use of Psilocybin and MDMAVancouver, British Columbia--(Newsfile Corp. - February 6, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (\"Lobe\" or the \"Company\"), a North American Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today congratulated the people of Australia for the decision by the TGA (Therapeutic Goods Administration) to reschedule Psilocybin and MDMA so that trained physicians may prescribe the psychedelics for patients across the country.Philip J. Young, Chairman and Chief Executive Officer of the Company stated, \"This is such an important step by a national government recognizing the value of these compounds in treating certain mental health conditions. As we prepare for a Ph 2 study in Australia in conjunction with iNGENu CRO in Chronic Cluster Headaches, it's heartening to know that there is already significant support for psychedelic compounds such as L-130, our proprietary psilocin product.\"The Australian TGA commented on their website. \"There is a need for access to new therapies for treatment-resistant conditions such as treatment-resistant depression and post-traumatic stress disorder.\" About Lobe Sciences Ltd.Lobe Sciences is a life sciences company focused on developing patient friendly practical psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using sub hallucinatory doses of psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.For further information please contact: Lobe Sciences Ltd.Philip J Young, [email protected]: (949) 505-5623NEITHER THE CSE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.This does not constitute an offer to sell or a solicitation of offers to buy any securities.Forward Looking Statements This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as \"will\", \"may\", \"should\", \"anticipate\", \"expect...